Neil Desai, Ph.D.

Neil Desai, Ph.D.

DirectoratWhitehawk Therapeutics· In proxies 2022–2025

Pay in FY2024-23% from the year before · Whitehawk Therapeutics stock +56.2% the same year

Neil Desai, Ph.D. was paid $1.7M in FY2024 (Dec), down 23%. Whitehawk Therapeutics stock rose 56.2% that year.

Pay$100 in the stock at the end of FY21 → $13
Pay is from the Summary Compensation Table of each Whitehawk Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Whitehawk TherapeuticsPublic company · 4 yr
    • Director2022 – Present · 4 yrStock in role -86%

Roles come from the proxy statements of each company.

Boards1

  • Whitehawk TherapeuticsDirector · 4 yr on the boardNot independent—Paid as an executive

Board seats come from each company's latest proxy statement.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?